Advertisement

Impact of ocular hypotensive lipids on clinically significant diabetic macular edema

Impact of ocular hypotensive lipids on clinically significant diabetic macular edema

Eur J Ophthalmol 2012; 22(5): 709 - 713

Article Type: ORIGINAL ARTICLE

DOI:10.5301/ejo.5000109

Authors

Anu S. Patel, Chirag C. Patel, Anju Goyal, Anupama Anchala, Sean Adrean, Bret Hughes, Tamer H. Mahmoud

Abstract

Purpose. To study the impact of ocular hypotensive lipids (OHL) on the incidence, progression, and response to treatment of clinically significant diabetic macular edema (CSDME). Methods. A total of 379 patients (232 female, 147 male) with a history of diabetes mellitus (DM) and primary open-angle glaucoma (POAG) were identified and included in the study. Patients were stratified into groups based on CSDME development and OHL exposure. Main outcome measures included time to development of CSDME, total duration of OHL exposure, and duration of DM and POAG.  Results. Seven patients (1.8%) developed CSDME after OHL exposure (group 1A), 15 (4.0%) developed CSDME prior to OHL exposure (group 1B), and 197 (52.0%) were treated with OHL but never developed CSDME (group 2). Of patients not exposed to OHL, 22 (5.8%) developed CSDME (group 3) and 138 (36.4%) did not (group 4). Mean duration of DM was longer (p<0.0001) in patients who developed CSDME (20.2 years) compared to patients who did not (12.4 years). There was no difference (p=0.67) in the amount of OHL exposure between patients who developed CSDME (4.1 years) and patients who did not (4.6 years). Once developed, there was no difference in the interval until CSDME resolution between OHL treated (17.8 mo) and untreated (12.7 mo) patients (p=0.36). Conclusions. The CSDME development correlated most strongly with the duration of diabetes, irrespective of OHL use. Ocular hypotensive lipids treatment of POAG seems not to affect the incidence, progression, or response to treatment of CSDME in diabetes.

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36.00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Patel, Anu S. [PubMed] [Google Scholar]
    Kresge Eye Institute, Department of Ophthalmology, Wayne State University School of Medicine, Detroit, Michigan - USA
  • Patel, Chirag C. [PubMed] [Google Scholar]
    Kresge Eye Institute, Department of Ophthalmology, Wayne State University School of Medicine, Detroit, Michigan - USA
  • Goyal, Anju [PubMed] [Google Scholar]
    Kresge Eye Institute, Department of Ophthalmology, Wayne State University School of Medicine, Detroit, Michigan - USA
  • Anchala, Anupama [PubMed] [Google Scholar]
    Kresge Eye Institute, Department of Ophthalmology, Wayne State University School of Medicine, Detroit, Michigan - USA
  • Adrean, Sean [PubMed] [Google Scholar]
    Kresge Eye Institute, Department of Ophthalmology, Wayne State University School of Medicine, Detroit, Michigan - USA
  • Hughes, Bret [PubMed] [Google Scholar]
    Kresge Eye Institute, Department of Ophthalmology, Wayne State University School of Medicine, Detroit, Michigan - USA
  • Mahmoud, Tamer H. [PubMed] [Google Scholar]
    Kresge Eye Institute, Department of Ophthalmology, Wayne State University School of Medicine, Detroit, Michigan - USA

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.